文献速递肾移植

抗IL-6抗体Clazakizumab治疗晚期抗体介导的肾移植排斥反应:随机临床试验

A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.
PubMed 文献 · J Am Soc Nephrol · 2020-12-18

该2期随机先导试验评估抗IL-6抗体Clazakizumab在晚期抗体介导排斥反应(ABMR)中的安全性和疗效。20例肾移植受者随机接受Clazakizumab或安慰剂12周,随后开放扩展40周。活动治疗组5例(25%)发生严重感染事件,2例(10%)发生憩室病并发症导致试验退出;Clazakizumab组供体特异性抗体显著下降,eGFR下降斜率在A阶段较安慰剂组减缓(-0.96 vs -2.43 ml/min/1.73m2/月,P=0.04)。

要点

  • Clazakizumab可显著降低供体特异性抗体并减缓eGFR下降。
  • 严重感染事件发生率为25%,需谨慎选择患者并监测。
  • 部分患者组织学及分子学ABMR活动度得到缓解。

核心结论

  • Clazakizumab在晚期ABMR中显示出潜在获益,可降低供体特异性抗体、减缓eGFR下降并改善组织学活动度,但安全性数据提示需谨慎选择患者和监测感染。

研究设计与样本

  • 2期随机先导试验,纳入20例肾移植后≥365天、供体特异性抗体阳性且经活检证实的晚期ABMR受者,1:1随机接受Clazakizumab 25 mg或安慰剂每4周皮下注射12周(A阶段),随后40周开放扩展所有患者接受Clazakizumab(B阶段)。

主要发现

  • 活动治疗组5例(25%)发生严重感染事件,2例(10%)发生憩室病并发症导致试验退出。
  • Clazakizumab组供体特异性抗体显著下降,长期治疗可调节排斥相关基因表达模式。
  • 18例患者51周活检显示7例(38.9%)分子学ABMR评分转阴,5例(27.8%)毛细血管C4d沉积消失,4例(22.2%)形态学ABMR活动度缓解。
  • A阶段Clazakizumab组eGFR下降斜率较安慰剂组减缓(-0.96,95%CI -1.96至0.03 vs -2.43,95%CI -3.40至-1.46 ml/min/1.73m2/月,P=0.04)。
  • B阶段从安慰剂转换为Clazakizumab的患者eGFR下降斜率改善,与初始Clazakizumab组无显著差异。

临床怎么用

  • 对于晚期ABMR肾移植受者,Clazakizumab可能作为降低供体特异性抗体和减缓肾功能下降的候选治疗,但需严格筛选患者并密切监测感染并发症。

局限性

  • 样本量小(20例),为先导试验,疗效结论需更大规模研究验证。
  • 开放扩展阶段无对照,长期安全性数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Late antibody-mediated rejection (ABMR) is a leading cause of transplant failure. Blocking IL-6 has been proposed as a promising therapeutic strategy. METHODS: We performed a phase 2 randomized pilot trial to evaluate the safety (primary endpoint) and efficacy (secondary endpoint analysis) of the anti-IL-6 antibody clazakizumab in late ABMR. The trial included 20 kidney transplant recipients with donor-specific, antibody-positive ABMR ≥365 days post-transplantation. Patients were randomized 1:1 to receive 25 mg clazakizumab or placebo (4-weekly subcutaneous injections) for 12 weeks (part A), followed by a 40-week open-label extension (part B), during which time all participants received clazakizumab. RESULTS: Five (25%) patients under active treatment developed serious infectious events, and two (10%) developed diverticular disease complications, leading to trial withdrawal. Those receiving clazakizumab displayed significantly decreased donor-specific antibodies and, on prolonged treatment, modulated rejection-related gene-expression patterns. In 18 patients, allograft biopsies after 51 weeks revealed a negative molecular ABMR score in seven (38.9%), disappearance of capillary C4d deposits in five (27.8%), and resolution of morphologic ABMR activity in four (22.2%). Although proteinuria remained stable, the mean eGFR decline during part A was slower with clazakizumab compared with placebo (-0.96; 95% confidence interval [95% CI], -1.96 to 0.03 versus -2.43; 95% CI, -3.40 to -1.46 ml/min per 1.73 m2 per month, respectively, P=0.04). During part B, the slope of eGFR decline for patients who were switched from placebo to clazakizumab improved and no longer differed significantly from patients initially allocated to clazakizumab. CONCLUSIONS: Although safety data indicate the need for careful patient selection and monitoring, our preliminary efficacy results suggest a potentially beneficial effect of clazakizumab on ABMR activity and progression.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Doberer K, Duerr M, Halloran PF, et al. A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2020. PMID: 33443079. doi:10.1681/ASN.2020071106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。